Prevalence and diagnostic reliability of BRAF, RAS mutations, and RET/PTC rearrangements in a Latin American public health service population with thyroid nodular disease
Authors:
Open Access
- 1 August 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (8) , e0329407
Abstract
Despite their high prevalence and generally benign nature in most cases, the investigation of thyroid nodules still presents potential diagnostic pitfalls, especially in cases with indeterminate cytology results. The performance of molecular markers of thyroid cancer may vary across centers and populations. This study aimed to verify the prevalence of mutations in the BRAF, and RAS genes, and RET/PTC rearrangements in patients undergoing fine-needle aspiration biopsy (FNAB) for thyroid nodule evaluation in a real-world public health service population. Point mutations and rearrangements were detected by Sanger DNA sequencing. A total of 231 thyroid nodules in 220 patients were evaluated, being 86.8% females and a mean age of 55.6 ± 13.9 years. For molecular analysis, high-quality DNA and RNA were obtained from 200 samples. Mutations or rearrangements in target genes were identified in 14% of the 200 samples evaluated. The frequency of the BRAF-like mutations was 5.5%, detected in 9 out of 17 malignant nodules (52.9%) and one in a benign nodule (0.7%). Fourteen RAS-like mutations were identified in benign nodules (57.1% HRAS, 21.5% NRAS and 21.5% KRAS) and only one was present in a malignant nodule (5.9%). Considering only nodules with indeterminate cytology (Bethesda III and IV, n = 53), 9 mutations were detected, 6 in benign histology (all RAS-like), 1 in malignant histology (BRAF-like), and 2 still unoperated, therefore without a histopathological diagnosis. This research concludes that the presence of the BRAF V600E mutation could be useful in supporting the diagnosis of thyroid cancer, due to its high positive predictive value, since 89% of nodules with BRAF V600E mutation were malignant. Additionally, clinical criteria should be established to determine which nodules with RAS-like mutations require closer follow-up, particularly those with indeterminate cytology.Keywords
Funding Information
- CNPq (Edital Universal 2018)
- UFCSPA (Edital PROPPG nº 44/2024)
This publication has 34 references indexed in Scilit:
- The Bethesda System for Reporting Thyroid Cytopathology2023
- Overview of the 2022 WHO Classification of Thyroid NeoplasmsEndocrine Pathology, 2022
- Cost analysis of reflexive versus selective molecular testing for indeterminate thyroid nodulesSurgery, 2022
- Frequency of Thyroid Hormone Replacement After Lobectomy for Differentiated Thyroid CancerEndocrine Practice, 2021
- Postoperative thyroid hormone supplementation rates following thyroid lobectomyThe American Journal of Surgery, 2020
- Multiplatform molecular test performance in indeterminate thyroid nodulesDiagnostic Cytopathology, 2020
- Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7‐gene panel test in 1172 thyroid FNAs deriving from different hospitals in South ItalyCancer Cytopathology, 2019
- Special issue: PI3K/Akt signaling in human cancerSeminars in Cancer Biology, 2019
- Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodulesSurgery, 2019
- Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristicsCancer Cytopathology, 2014